Gunderson Dettmer advised Theravance in a follow-on public offering of 5,500,000 shares at a price to the public of $27.00 per share for gross proceeds of approximately $148.5 million. Capital markets partner Jeff Vetter, corporate partner David Young, tax partner Jaime Narayan, and associates Colin Conklin and Tanya Tarczynski led the team advising Theravance.

The joint book-running managers included Morgan Stanley, J.P. Morgan and Cowen.

Theravance, which trades on the Nasdaq under the ticker symbol “TBPH,” is a diversified biopharmaceutical company focused on the discovery, development and commercialization of organ-selective medicines.